Performance status -0 - Asymptomatic - Page 3 of 5 Posts on Medivizor
Navigation Menu

Performance status -0 – Asymptomatic Posts on Medivizor

Looking for patients with relapse/unresponsive lymphoma to test a treatment combination

Posted by on Mar 29, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study is evaluating the best dose and side effects of mogamulizumab (Poteligeo) plus pembrolizumab (Keytruda) for relapsed or unresponsive lymphoma. The main outcomes to be measured will be the best dose and side effects of treatment, as well as survival without the tumor growing. This study is being conducted in Sacramento,...

Read More

Looking for children and young adults with Hodgkin lymphoma to test a new treatment.

Posted by on Mar 28, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This trial is examining the safety and effectiveness of pembrolizumab (Keytruda) in the treatment of children and young adults with classical Hodgkin lymphoma (HL). The main outcome to be measured will be a response to treatment. This trial is recruiting in the Republic of Korea and the United States. The details...

Read More

Looking for elderly patients with chronic lymphocytic leukemia to test a treatment combination

Posted by on Mar 16, 2019 in Leukemia | 0 comments

In a nutshell This trial is examining the effectiveness of ibrutinib and obinutuzumab with or without venetoclax in the treatment of older patients with chronic lymphocytic leukemia (CLL). The main outcome to be measured will be survival without cancer worsening. This trial is recruiting in the United States. The details Patients with CLL are often...

Read More

Searching for patients to try a new therapy for non-responsive lymphoma after stem-cell transplant.

Posted by on Mar 15, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study will investigate the effects of ibrutinib (Imbruvica) in patients with non-responsive lymphoma after a stem-cell transplant. The main outcome that will be measured is the time after treatment before patients experience cancer worsening. This trial is recruiting in the United States. The details Some patients with lymphoma lose...

Read More

Searching for patients to try a new therapy for non-responsive lymphoma after stem-cell transplant.

Posted by on Mar 15, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study will investigate the effects of ibrutinib (Imbruvica) in patients with non-responsive lymphoma after a stem-cell transplant. The main outcome that will be measured is the time after treatment before patients experience cancer worsening. This trial is recruiting in the United States. The details Some patients with lymphoma...

Read More

Searching for patients with previously untreated DLBCL to try this new treatment combination

Posted by on Mar 15, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study is comparing the effectiveness of R-CHOP chemotherapy with or without enzastaurin (Kinenza) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). The main outcome to be measured will be overall survival at the end of the study. The details The current standard first-line treatment for DLBCL is R-CHOP...

Read More

Searching for patients with relapsed or unresponsive classical HL to try this new treatment option

Posted by on Mar 15, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This Phase 3 trial is evaluating the effectiveness of brentuximab vedotin (Adcetris) with or without nivolumab (Opdivo) for patients with relapsed or unresponsive classical Hodgkin’s lymphoma (cHL). The main outcome to be measured will be survival outcomes at 4 years after treatment. The details Treatment remains...

Read More

Looking for patients with relapsed or unresponsive lymphoma to test a cell therapy

Posted by on Mar 4, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 1 trial is investigating the effectiveness and safety of a new T-cell therapy for relapsed or unresponsive lymphoma. The main outcome to be measured will be the side effects of treatment and long-term survival. This study is being conducted in Chapel Hill, North Carolina, United States. The details In cancer therapy,...

Read More

Looking for patients with relapsed or unresponsive mantle cell lymphoma to test a new treatment

Posted by on Feb 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 trial is evaluating the safety and effectiveness of a new targeted therapy for relapsed or unresponsive mantle cell lymphoma (MCL). The main outcome to be measured is the overall response rate to treatment. The details Ibrutinib (Imbruvica) is a commonly used therapy for patients with relapsed or refractory MCL. This...

Read More

Searching for patients with Hodgkin lymphoma to try a new combination treatment

Posted by on Feb 25, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study will investigate the effects of a new combination of pembrolizumab (Keytruda) and MK-4280 for the treatment of Hodgkin lymphoma (HL). Side effects and response to treatment will be the main effects measured. The details Pembrolizumab and MK-4280 are both targeted therapies for blood cancers. This means that they specifically...

Read More

Looking for patients with B-cell non-Hodgkin’s lymphoma to test a new treatment option

Posted by on Feb 9, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This trial is examining the safety and effectiveness of mosunetuzumab plus polatuzumab vedotin for B-cell non-Hodgkin’s lymphoma (NHL). The main outcomes to be measured will be the complete response rate and the occurrence of side effects after treatment. This study is recruiting in Miami, Florida, New York City, New York, and Duarte,...

Read More

Searching for patients with chronic lymphocytic leukemia to test zanubrutinib compared to ibrutinib

Posted by on Jan 27, 2019 in Leukemia | 0 comments

In a nutshell This trial is looking at the effectiveness of zanubrutinib compared to ibrutinib in the treatment of patients with unresponsive or relapsed chronic lymphocytic leukemia (CLL). The main outcome to be measured will be overall response rate. The study will be carried out in the United States.  The details Chronic...

Read More